TO STUDY THE CLINICAL EFFICACY OF PATHOGENETIC THERAPY IN WOMEN WITH GENITAL ENDOMETRIOSIS.

Аннотация

Endometriosis is a chronic hormone—dependent disease characterized by an inflammatory reaction [1,2]. The chronic, progressive, and recurrent nature of endometriosis makes it extremely urgent to search for new areas of targeted therapy for genital endometriosis that have high therapeutic efficacy and minimal side effects. Currently, the standard for specific therapy of endometriosis is the use of dienogest 2 mg, which is a hybrid progestogen that combines the best properties of the norsteroid and progesterone groups [5,7]. Currently, the main goal of modern therapy for genital endometriosis is not only the suppression of the level of estrogens synthesized by the ovaries, but also the pathogenetic effect on the site of endometriosis itself (suppression of local estrogen production, overcoming progesterone resistance, antiproliferative and antiangiogenic effects, increased apoptosis).